We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
- Authors
Mozas, Pablo; Sorigué, Marc; Rivas‐Delgado, Alfredo; Rivero, Andrea; Correa, Juan G.; Castillo, Carlos; Nadeu, Ferran; Bataller, Alex; Giné, Eva; Baumann, Tycho; Delgado, Julio; Villamor, Neus; Campo, Elias; Magnano, Laura; Sancho, Juan‐Manuel; López‐Guillermo, Armando
- Abstract
This is the first study analyzing the interval between frontline treatment and the second relapse (PFS2) in follicular lymphoma. The PFS2 was <2 years in 41 patients (46%), 2-5 years in 29 patients (33%), and >5 years in 19 patients (21%). Although not statistically significant, the CR rate after frontline and second-line treatments was higher for patients with a PFS2 > 5 years (95 and 84% for first- and second-line treatment), compared with those with a PFS2 2-5 years and <2 years.
- Subjects
HEMATOPOIETIC stem cell transplantation; BIOMARKERS
- Publication
European Journal of Haematology, 2021, Vol 106, Issue 3, p428
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13556